- Trials with a EudraCT protocol (44,351)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
44,351 result(s) found.
Displaying page 1,541 of 2,218.
EudraCT Number: 2020-002206-10 | Sponsor Protocol Number: APHP190891 | Start Date*: 2020-07-07 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: A prospective study of the safety and efficacy of the use of a Lipiodol Emulsion for the embolization of inflammatory hypervascularizations observed in patients with articular or abarticular pain i... | ||
Medical condition: Adult patients with articular or abarticular intractable pain in the knee | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000880-63 | Sponsor Protocol Number: na | Start Date*: 2021-03-11 |
Sponsor Name:Skåne University Hospital, department of rheumatology in Lud and Malmö | ||
Full Title: COVID-19 vaccine in patients with inflammatory rheumatic diseases: The impact of immunomodulating treatments on the antibody response, T cells response and protection against infection (COVID19-REUMA) | ||
Medical condition: rheumatoid arthritis, SLE, systemic vasculitis, systemic sclerosis, spondylarthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006126-52 | Sponsor Protocol Number: CUV803 | Start Date*: 2023-02-15 | |||||||||||
Sponsor Name:CLINUVEL EUROPE LIMITED | |||||||||||||
Full Title: A Phase IIa, Open Label, Proof of Concept Study to Evaluate the Safety of Aqueous Afamelanotide Solution in Patients with acute Arterial Ischaemic Stroke (AIS) who are ineligible for Intravenous Th... | |||||||||||||
Medical condition: Arterial Ischaemic Stroke (AIS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005468-14 | Sponsor Protocol Number: OPHT-081214 | Start Date*: 2015-02-24 | |||||||||||
Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology | |||||||||||||
Full Title: Latanoprost preserved versus unpreserved: effect on tear film thickness as measured with OCT | |||||||||||||
Medical condition: glaucoma and ocular hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002171-19 | Sponsor Protocol Number: HEVACC | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck, Institut für Virologie | |||||||||||||
Full Title: Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost | |||||||||||||
Medical condition: Immunization for SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004502-93 | Sponsor Protocol Number: CA209-026 | Start Date*: 2014-04-23 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer | ||||||||||||||||||
Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed) CZ (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) RO (Ongoing) PL (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002704-41 | Sponsor Protocol Number: 18498A | Start Date*: 2020-03-13 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: A randomised, double-blind, parallel-group, active controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with par... | |||||||||||||
Medical condition: Major depressive disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) EE (Completed) LV (Completed) BG (Completed) SK (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004003-41 | Sponsor Protocol Number: 217354 | Start Date*: 2022-02-11 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase III, randomized, open-label, active vaccine-controlled crossover study to evaluate the reactogenicity, safety and immune response of unadjuvanted RSV maternal vaccine in healthy non-pregnan... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (prevention of RSV-associated lower respiratory tract illnesses (LRTIs)) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003408-65 | Sponsor Protocol Number: | Start Date*: 2016-08-26 | ||||||||||||||||
Sponsor Name:University of Edinburgh [...] | ||||||||||||||||||
Full Title: Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial) | ||||||||||||||||||
Medical condition: Heavy menstrual bleeding | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000955-25 | Sponsor Protocol Number: PSS2015/EFFET-LEHEUP/SKJ | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Centre Hospitalier Régional Universitaire de Nancy | |||||||||||||
Full Title: Evaluation of the efficiency of folinic acid in children with autism spectrum disorders: a pilot study "EFFET" | |||||||||||||
Medical condition: Autism spectrum disorders | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001910-33 | Sponsor Protocol Number: AGAL02603 | Start Date*: 2007-12-05 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Multicenter, Multinational Study of the Effects of Fabrazyme® (agalsidase beta) Treatment on Lactation and Infants | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: In utero, Newborns, Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002777-29 | Sponsor Protocol Number: M17-377 | Start Date*: 2022-10-14 | |||||||||||
Sponsor Name:AbbVie Inc | |||||||||||||
Full Title: A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects in Japan with Moderate to S... | |||||||||||||
Medical condition: Moderate to Severe Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016875-30 | Sponsor Protocol Number: VA 2009/40 | Start Date*: 2010-04-12 | |||||||||||
Sponsor Name:CRLC VAL D’AURELLE | |||||||||||||
Full Title: Essai de phase II évaluant l’association de gemcitabine, trastuzumab et erlotinib en 1ère ligne de traitement par chimiothérapie des patients atteints d’un adénocarcinome du pancréas métastatique | |||||||||||||
Medical condition: adénocarcinome du pancréas métastatique | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004749-18 | Sponsor Protocol Number: 201311LM | Start Date*: 2014-03-05 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Home abortion up to 10 weeks of gestation | ||
Medical condition: Unwanted pregnancy and induced abortion | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-000781-38 | Sponsor Protocol Number: sempa1 | Start Date*: 2019-05-07 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in patients with type 2 diabetes – A randomized Trial | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005745-16 | Sponsor Protocol Number: 77119 | Start Date*: 2021-03-22 | |||||||||||
Sponsor Name:Steno Diabetes Center Copenhagen | |||||||||||||
Full Title: Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People with Type 1 Diabetes: A Randomized, Open-Label, Two-Period Crossover Outpatient Study | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001487-38 | Sponsor Protocol Number: 16.0247 | Start Date*: 2017-06-30 |
Sponsor Name:St George's, University of London | ||
Full Title: Babies born Early Antibody Response to Men B vaccination: BEAR Men B | ||
Medical condition: This study is looking at the vaccine responses of premature infants to the Men B vaccine. | ||
Disease: | ||
Population Age: Preterm newborn infants, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002184-97 | Sponsor Protocol Number: CABOCOL-01 | Start Date*: 2019-10-10 | |||||||||||
Sponsor Name:Centre François Baclesse | |||||||||||||
Full Title: A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure | |||||||||||||
Medical condition: Recurrent unresectable or metastatic cervix carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000580-14 | Sponsor Protocol Number: UC-0105/1501 | Start Date*: 2015-05-12 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A single arm, open-label, phase II study to assess the efficacy of rucaparib in metastatic breast cancer patients with a BRCAness genomic signature. | |||||||||||||
Medical condition: Patients with progressing metastatic breast cancer pretreated with at least one line of chemotherapy at the metastatic setting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001594-14 | Sponsor Protocol Number: FITC-ADA-CU-01 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: Prospective, single-centre, open-label, one-arm clinical trial, phase I/IIa, to assess the safety and tolerability and to investigate the predictive power of FITC-Adalimumab, when topically applied... | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
